Novel Molecular Imaging Technology Could Improve Tumor Margin Assessment During Breast Cancer Surgery
Executive Summary
A novel molecular imaging technology for intraoperative assessment of tumor margins during breast cancer surgery is positioned to not only improve patient outcomes, but to also reduce costs by eliminating the need for repeat surgeries. Lightpoint Medical has already received the CE mark for its product, which could be developed for use in other cancers, and a US launch could come as early as the first quarter of 2016.